Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results

19525 Background: Radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan (YIT), a radio-labelled anti-CD20 antibody, was shown to be highly effective in systemic B-cell lymphomas. We for the first...